
==== Front
PeerJ
PeerJ
peerj
PeerJ
2167-8359
PeerJ Inc. San Diego, USA

18063
10.7717/peerj.18063
Biochemistry
Cardiology
Nephrology
Key regulators of vascular calcification in chronic kidney disease: Hyperphosphatemia, BMP2, and RUNX2
Liang Xinhua 1
Li Yankun 1
Wang Peng wangpeng@gdmu.edu.cn
2
Liu Huafeng liuhf@gdmu.edu.cn
2
1 Affiliated Hospital of Guangdong Medical University, Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Zhanjiang, Guangdong Province, China
2 Affiliated Hospital of Guangdong Medical University, Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Zhanjiang, Guangdong, China
Capusa Cristina
19 9 2024
2024
12 e1806326 2 2024
19 8 2024
©2024 Liang et al.
2024
Liang et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.

Vascular calcification is quite common in patients with end-stage chronic kidney disease and is a major trigger for cardiovascular complications in these patients. These complications significantly impact the survival rate and long-term prognosis of individuals with chronic kidney disease. Numerous studies have demonstrated that the development of vascular calcification involves various pathophysiological mechanisms, with the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs) being of utmost importance. High phosphate levels, bone morphogenetic protein 2 (BMP2), and runt-related transcription factor 2 (RUNX2) play crucial roles in the osteogenic transdifferentiation process of VSMCs. This article primarily reviews the molecular mechanisms by which high phosphate, BMP2, and RUNX2 regulate vascular calcification secondary to chronic kidney disease, and discusses the complex interactions among these factors and their impact on the progression of vascular calcification. The insights provided here aim to offer new perspectives for future research on the phenotypic switching and osteogenic transdifferentiation of VSMCs, as well as to aid in optimizing clinical treatment strategies for this condition, bearing significant clinical and scientific implications.

Vascular calcification secondary to chronic kidney disease
Hyperphosphatemia
BMP2
RUNX2
National Natural Science Foundation of China82000651, 82170691, 81974095 and 82370705 Guangdong Basic and Applied Basic Research Foundation2022A1515012209 Research Start-up Funds for High-level Talents in the Affiliated Hospital of Guangdong Medical UniversityGCC2022038 Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases2022B1212030003 National Clinical Key Specialty Construction ProjectThis work was supported by grants from the National Natural Science Foundation of China (82000651, 82170691, 81974095 and 82370705), the Guangdong Basic and Applied Basic Research Foundation (2022A1515012209), the Research Start-up Funds for High-level Talents in the Affiliated Hospital of Guangdong Medical University (GCC2022038), the Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases (2022B1212030003), and the National Clinical Key Specialty Construction Project (Institute of Nephrology, Affiliated Hospital of Guangdong Medical University). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
==== Body
pmcIntroduction

Currently, cardiovascular complications are the leading cause of death among patients with chronic kidney disease (CKD) and those with end-stage renal disease (ESRD), accounting for 30%–50% of all fatalities (Vogt, Haffner & Leifheit-Nestler, 2019; Yamada & Giachelli, 2017). In the later stages of CKD, the incidence of cardiovascular complications significantly increases due to the decline in renal function. This decline impairs the kidney’s ability to manage the metabolism of minerals such as calcium and phosphorus in the body, thereby accelerating vascular calcification (VC) and arteriosclerosis (Hénaut et al., 2018; Liu et al., 2014; Shroff, Long & Shanahan, 2013). VC in CKD patients can occur in both the intima and the media of the vascular walls, and these two types of calcifications may occur concurrently, leading to an increased cardiovascular mortality rate in CKD patients (Anonymous, 2009; Viegas et al., 2019). There is ample clinical evidence to suggest that VC is significantly associated with the incidence and mortality of cardiovascular complications in patients with CKD and ESRD. It is considered one of the most effective independent predictors of cardiovascular risk in CKD patients (Alani, Tamimi & Tamimi, 2014; Blacher et al., 2001; Cozzolino et al., 2018). According to statistics from the United States Renal Data System (USRDS), the risk of cardiovascular complication-related mortality in ESRD patients undergoing dialysis is five to 30 times higher compared to the healthy population. Furthermore, the process of vascular calcification in CKD patients begins several years earlier (Collins et al., 2015; Goodman et al., 2000).

It is evident that vascular calcification poses a significant threat to the survival rate and quality of life of patients with chronic kidney disease. However, there is currently no effective clinical treatment available to reverse the progression of vascular calcification in patients with chronic kidney disease. Therefore, this review will provide a detailed introduction to the regulatory mechanisms and signaling molecules that have a significant impact on the progression of vascular calcification in chronic kidney disease. This will offer potential new strategies for subsequent downstream mechanism research and exploration of clinical treatment strategies.

Survey methodology

We have conducted an extensive search of the relevant literature published in last 20 years using various scientific search engines such as PubMed, Google Scholar, and Baidu Scholar, with search terms “chronic kidney disease with vascular calcification” and “osteogenic transdifferentiation”, to analyze the role of related osteogenic transcription factors such as BMP2 and RUNX2 in mediating the osteogenic transdifferentiation of vascular smooth muscle cells in the progression of chronic kidney disease with vascular calcification. During the retrieval process, we focused on the regulatory mechanisms of hyperphosphatemia, BMP2 and RUNX2 in chronic kidney disease with vascular calcification and the interconnection between the three. After carefully screening the retrieved literature, we only included publications that are relevant to the subject. Studies that did not meet the current inclusion criteria, were irrelevant to the topic, conference records, editorials, and reviews with insufficient data were excluded from the inclusion criteria.

Vascular calcification during the course of chronic kidney disease

VC, or vascular calcification, refers to the abnormal deposition of inorganic salts composed of calcium and phosphate ions in cardiovascular tissues such as the walls of blood vessels, the heart, and heart valves. It is commonly seen in aging, diabetes and end-stage renal disease. As the renal function of patients with chronic kidney disease declines, the disorder in phosphorus excretion leads to bone metabolism disorders such as secondary hyperparathyroidism. The reduction in renal phosphorus excretion and increased secretion of calcium and phosphorus metabolism-regulating hormones such as parathyroid hormone (PTH) and FGF23 (Fibroblast Growth Factor 23) jointly promote disorders in the metabolism of minerals like calcium and phosphorus in the body, leading to renal osteodystrophy. Vascular calcification caused by calcium and phosphorus deposition within the vascular walls is one of the manifestations of renal bone metabolism disorders. The most crucial role in the pathological process leading to VC formation is played by the osteogenic transdifferentiation of VSMCs. This process involves the transformation of contractile type vascular smooth muscle cells into secretory osteoblast-like cells, destruction of intracellular actin filaments, and deposition of large amounts of minerals such as calcium and phosphorus in the muscular layer, ultimately leading to adverse outcomes such as vascular wall stiffness and luminal narrowing (Moe et al., 2003; Smith, 2016). The prevalent clinical view is that VC is one of the characteristics of advanced chronic kidney disease-mineral and bone disorder (CKD-MBD). In addition to VC, symptoms of abnormal serum biochemical indicators such as hyperphosphatemia, hypercalcemia, and bone disorders are also present. Among these characteristics, VC is considered a hallmark feature of CKD-MBD (Moe et al., 2006; Yamada & Giachelli, 2017). Clinically, VC is defined as the pathological deposition of calcium phosphate crystals in the cardiovascular system. In late-stage CKD patients, there are several circulating factors that induce VC, collectively referred to as the uremic milieu (Demer & Tintut, 2008; Hénaut et al., 2018). It has been found that due to the decline in renal excretory function, the patient’s serum contains very high levels of uremic toxins and inorganic phosphates, both of which have a strong inductive effect on VC. In addition, there are multiple circulating pro-VC factors, which ultimately induce the deposition of inorganic salts of calcium and phosphate in the intimal and medial layers of blood vessels (Ciceri & Cozzolino, 2021). The impact of VC on cardiovascular outcomes in CKD patients is highly related to the location of the mineral deposits. Intimal calcification reflects, to some extent, the burden of arteriosclerotic plaques and is a significant predictor of cardiovascular event mortality in late-stage CKD patients (Viegas et al., 2019). Intimal calcification can ultimately lead to vascular wall stiffening, increased pulse pressure, left ventricular hypertrophy, and even heart failure, adversely affecting the quality of life and cardiovascular outcomes in the CKD population (Raggi et al., 2007). Therefore, a deeper understanding of the mechanisms of pathological calcification during the late stages of CKD is particularly important, in order to reduce the risk of adverse cardiovascular outcomes, improve the quality of life, and extend the life expectancy of the CKD population.

The molecular mechanism of vascular calcification

The mechanisms that promote the development of vascular calcification in chronic kidney disease have been found to share similarities with normal physiological bone formation (Alves et al., 2014; Doherty & Detrano, 1994). These include the transdifferentiation of osteochondrogenic cells, apoptosis of vascular smooth muscle cells, extracellular matrix remodeling, and the release of extracellular vesicles, with the osteochondrogenic transdifferentiation of VSMCs playing a particularly crucial role (Lanzer et al., 2014; Shanahan et al., 2011). It has been observed that these various molecular mechanisms can act concurrently in the process of VC, without necessarily being mutually exclusive(Johnson, Leopold & Loscalzo, 2006).

Disturbances in the homeostasis of mineral metabolism and high concentrations of phosphate are considered major determinants in the progression of VC in CKD patients (Schlieper et al., 2016; Shanahan et al., 2011). Phosphate complexes first activate intracellular signaling pathways that precede calcification (Alesutan et al., 2017; Voelkl et al., 2018b). High serum levels of phosphate upregulate the expression of type III sodium-dependent phosphate transport protein (Pit-1) on VSMC membranes, increasing intracellular inorganic phosphate (Pi) levels. This, in turn, activates intracellular PI3K/AKT and ERK1/2 signaling pathways, inducing an increase in RUNX2 expression and promoting the osteogenic transdifferentiation of VSMCs (Chavkin et al., 2015; Lee, Lee & Jeon, 2020). Osteogenic transdifferentiation refers to the process by which VSMCs transform into cells with an osteoblast-like phenotype through selective gene expression. During this process, the expression of VSMC-specific proteins such as α-smooth muscle actin (α-SMA) and smooth muscle protein 22α (SM22α) decreases, while the expression of osteoblast/chondrocyte-specific proteins like osteopontin (OPN) and osteocalcin (OCN) increases (Steitz et al., 2001).

BMP2 and RUNX2 play extremely important roles in this process. BMP2 is a member of the transforming growth factor (TGF-β) protein family and has been shown to activate Runx2 in various cell types, playing an essential role in bone formation and repair (Durham et al., 2018; Orth-Alampour et al., 2021; Tsuji et al., 2006). The pivotal role of these pathways highlights potential targets for therapeutic interventions aimed at mitigating VC in patients with CKD.

The main cause of vascular calcification: high phosphorus

Among the various factors that can induce vascular calcification in patients with chronic kidney disease, hyperphosphatemia shows the most significant correlation with VC secondary to CKD, and it is a quintessential feature of the disorder in mineral and bone metabolism associated with CKD (Block et al., 2004; Taniguchi et al., 2013). Under normal circumstances, the level of serum inorganic phosphorus is mainly regulated by physiological processes such as the absorption of phosphorus by the intestines, filtration and reabsorption by the renal tubules, and the exchange of substances inside and outside cells, among which the role of the kidneys is crucial. With the decline in renal function in the later stages of patients with chronic kidney disease, the kidney’s ability to excrete phosphorus decreases, leading to a large accumulation of phosphates in the internal environment. This activates the osteogenic transdifferentiation process within vascular smooth muscle cells, prompting the transformation of vascular smooth muscle cells into an osteoblast-like cell phenotype, increasing intracellular calcium ion levels, and consequently leading to vascular wall calcification, vessel narrowing, and increased vascular stiffness, among other adverse outcomes (Tonelli, Pannu & Manns, 2010). As renal function declines in the later stages of CKD, serum inorganic phosphate levels rise, which then induces a phenotypic transformation of vascular smooth muscle cells into osteoblast-like cells, playing a crucial role in promoting VC (Luong et al., 2018; Voelkl et al., 2018b). Osteoblast-like cells express a variety of osteogenic transcription factors, such as msh homeobox 2 (MSX2), RUNX2, and Osterix (Osx), with RUNX2 playing a decisive role in VC secondary to CKD (Alesutan et al., 2017; Chen & Moe, 2015; Voelkl et al., 2013). Research by Speer et al. (2010) and Sun et al. (2012) has found that knocking down the expression of RUNX2 in VSMCs with siRNA can inhibit osteochondrogenic transdifferentiation of VSMCs and VC. Various osteogenic transcription factors can further stimulate VSMCs to express osteoblast-specific proteins, such as osteocalcin, bone morphogenetic protein 2 and alkaline phosphatase (ALP), especially BMP2, which significantly promotes the uptake of phosphate by VSMCs and their phenotypic changes (Leibrock et al., 2016; Li, Yang & Giachelli, 2008; Shanahan et al., 1999).

Furthermore, in the process of VC secondary to CKD, high levels of Pi activate various intracellular signaling pathways that regulate VC. In VSMCs, the uptake of Pi is primarily mediated by type III sodium-dependent phosphate co-transporters Pit1 and Pit2 (Lang et al., 2013; Shanahan et al., 2011). Activation of the ERK1/2 signaling pathway may be related to downstream signaling of Pit1 and upregulates the expression of RUNX2 and ALP in VSMCs (Chavkin et al., 2015; Li, Yang & Giachelli, 2006; Speer et al., 2009). Recent studies have found that Pit2 may upregulate the expression of osteoprotectin, inhibiting the progression of VC (Makarović et al., 2015; Yamada et al., 2018). Elevated serum Pi levels also activate the nuclear transcription factor NF-κB signaling pathway (Yoshida et al., 2017; Zhao et al., 2012). Research by Voelkl et al. (2018a) has found that the NF-κB signaling pathway can promote osteogenic transdifferentiation of VSMCs by upregulating the expression of osteogenic transcription factors MSX2 and RUNX2, thereby inducing an increase in ALP expression. The WNT/β-catenin signaling pathway is considered pivotal in VC signaling, and its activation upon elevated extracellular Pi levels can upregulate the expression of RUNX2 and Pit1, thereby promoting osteogenic transdifferentiation of VSMCs (Cai et al., 2016; Yao et al., 2015). Research by Deng et al. (2016) and Martínez-Moreno et al. (2012) has shown that using specific inhibitors of the Wnt/β-catenin signaling pathway, such as Dickkopf-related protein 1 (DKK1) and secreted frizzled-related proteins (SFRPs), can inhibit the calcification of VSMCs (Deng et al., 2016; Martínez-Moreno et al., 2012).

Studies also suggest the involvement of inflammatory cytokines in the regulation of VC secondary to CKD in the context of hyperphosphatemia. Research by Yamada et al. (2014) has found that a high phosphate load can induce local inflammation in cultured VSMCs, producing pro-inflammatory cytokines such as tumor necrosis factor α, interleukin-1β(IL-1β), interleukin-6(IL-6), BMP2 and others (Agharazii et al., 2015; Yamada et al., 2014). Research by Lee et al. (2010) has found that TNF-α can promote osteogenic transdifferentiation of VSMCs by upregulating the expression of MSX2 through the NF-κB signaling pathway. Other studies have found that IL-6 can induce osteogenic transdifferentiation of VSMCs through the activation of the WNT/β-catenin and STAT3 signaling pathways (Abedin et al., 2006; Lin et al., 2016; Sun et al., 2017). Additionally, research indicates that cell apoptosis signaling pathways are activated during the regulation of VC secondary to CKD by hyperphosphatemia. Research by Qiu et al., (2017), Son et al. (2006) and Son et al. (2007) and others has found that high extracellular Pi levels can downregulate the expression of growth arrest-specific gene 6 (Gas6) and its receptor tyrosine kinase Axl in VSMCs, inhibit the activation of the Gas6/Axl/Akt anti-apoptotic signaling pathway, induce the deactivation of the anti-apoptotic protein Bcl2 and activation of the pro-apoptotic protein Bad, leading to apoptosis in VSMCs (Qiu et al., 2017; Son et al., 2006; Son et al., 2007). AMPK is considered an important upstream regulatory factor for Gas6 expression (Ma et al., 2019). Research by Xu et al. (2017) has shown that activation of AMP-activated protein kinase (AMPK) can inhibit the calcification of VSMCs, and the activity of AMPK decreases when extracellular Pi levels are elevated.

Therefore, hyperphosphatemia can be said to be a decisive factor in inducing VC secondary to CKD. Further exploration of the mechanism by which hyperphosphatemia regulates VC holds positive significance for the future discovery of diagnostic methods and treatment plans for VC secondary to CKD.

The role of BMP2 in the process of vascular calcification

Bone morphogenetic proteins are members of the transforming growth factor-β family, and current research progress indicates that multiple BMPs are involved in the regulatory process of VSMC calcification. For example, BMP2 and BMP4 are considered to be markers and driving factors of vascular calcification, yet the presence of BMP7 seems to help inhibit the progression of VC in the later stages of CKD (Yang et al., 2020). Wang EA, Sampath TK, and others were among the first to discover that BMPs promote ectopic bone formation, and later studies found a substantial expression of these proteins at sites of vascular calcification (Boström et al., 1993; Sampath & Reddi, 1981; Wang et al., 1990). Research by Scimeca et al. (2019) analyzed calcified plaques from 52 patients with carotid calcification, finding a significant correlation between the expression of BMP2 and the presence of unstable plaques. Other studies proved that BMP2 can enhance osteogenic transdifferentiation of VSMCs through its pro-inflammatory and pro-atherosclerosis effects, thereby promoting VC (Li, Yang & Giachelli, 2008; Yung et al., 2015). Studies by Liberman et al. (2011) showed that BMP2 upregulates the expression of the decisive osteogenic transcription factor RUNX2, promoting pathological calcium and phosphate accumulation in cultured human VSMCs through oxidative stress and endoplasmic reticulum stress mechanisms. Dalfino et al. (2010) and Rong et al. (2014) proposed that in late-stage CKD patients, the serum levels of BMP2 increase, and extracellular high Pi along with BMP2 can upregulate the expression of osteogenic transcription factors MSX2 and RUNX2 in VSMCs, promoting their transdifferentiation into osteoblast-like cells. This process found that β-catenin protein links high Pi, BMP2, and the WNT/β-catenin signaling pathway in the regulation of VC as a whole (Dalfino et al., 2010; Rong et al., 2014).

In addition, recent years’ research has found that BMP2 undergoes epigenetic modifications in the process of regulating VC. It is commonly believed that osteogenic reprogramming refers to the process in which the phenotype of VSMCs is transformed into that of osteoblasts through epigenetic modifications such as DNA methylation, without changing the gene sequence. Research by Chen et al. (2016) and Pons et al. (2009) indicates that DNA methylation and histone modifications are important regulatory factors in the osteogenic reprogramming process. Ouyang et al. (2021) found that, in the VSMCs of the aorta in a CKD mouse model, the expression of the DNA demethylase ALKBH1 was increased. ALKBH1 enhances the binding of the octamer-binding transcription factor Oct4 to the BMP2 promoter through demethylation modification of N6-methyladenine on the BMP2 promoter, thereby upregulating the expression of BMP2 and promoting osteogenic reprogramming of VSMCs as well as VC (Ouyang et al., 2021). Zeng et al. (2021) found that by inhibiting the activation of the ERK1/2 signaling pathway and upregulating microRNA-126-3p expression in VSMCs cultured from a mouse model of VC, microRNA-126-3p’s interference with BMP2 gene expression at the post-transcriptional level was enhanced, thus inhibiting osteogenic transdifferentiation of VSMCs. Moreover, Pei et al. (2020) found that microRNA-204 seems to also interfere with the expression of BMP2 genes at the post-transcriptional level during the osteogenic reprogramming of VSMCs. Research by Yanagawa et al. (2012) confirmed that microRNA-141 can inhibit BMP2-mediated signal transduction in VSMCs, thereby partially reversing VSMC calcification and osteogenic transdifferentiation.

Therefore, it is evident that BMP2 plays an extremely important role in the regulatory process of VC secondary to CKD. Clarifying the factors affecting the expression of BMP2 will promote the development of clinical treatment methods for this disease.

The role of RUNX2 in the process of vascular calcification

In the process of vascular calcification, Runt-related transcription factor 2 is commonly regarded as a decisive osteogenic transcription factor. Its upregulated expression in cardiovascular tissues is an important regulatory factor for adverse cellular events in the cardiovascular outcomes of patients with chronic kidney disease (Chen, Zhao & Wu, 2021). Research by Engelse et al. (2001) and Tyson et al. (2003) found a positive correlation between arterial calcification scores and upregulated expression of RUNX2 in both human and mouse models of VC. Recent studies have found that RUNX2 seems to act as a downstream molecule of various pro-osteogenic signaling pathways during the progression of VC. Under high phosphate conditions, the expression of RUNX2 in isolated mouse VSMCs is upregulated due to the activation of the PI3K/AKT signaling pathway, and the expression of RUNX2 is reduced when the PI3K/AKT pathway is inhibited using AKT inhibitors (Byon et al., 2008; Deng et al., 2015). In the research by Yang et al. (2018) experiments in both in vivo and in vitro mouse VSMCs suggested that the activation of the p38-MAPK signaling pathway appears to induce the binding and phosphorylation of RUNX2 with p38 MAPK, thereby enhancing the transcriptional activity of RUNX2 and promoting VSMC calcification and osteogenic transdifferentiation. Li et al. (2022) found that melatonin could inhibit the calcification of VSMCs by suppressing the activation of the NF-κB/CREB signaling axis, and thus preventing the binding of NF-κB to the RUNX2 promoter region.

Furthermore, in the regulation of VC, RUNX2 undergoes various post-translational modifications that can affect its regulatory functions (Chen, Zhao & Wu, 2021). Studies have found that the activated ERK/MAPK and p38-MAPK signaling pathways can mediate the phosphorylation of RUNX2, thereby enhancing its transcriptional activity (Greenblatt et al., 2010; Xiao et al., 2000; Yang et al., 2018). Similarly, the transcriptional coactivator p300, which possesses histone acetyltransferase (HAT) activity, enhances the stability of RUNX2 through acetylation, making it less susceptible to degradation by the ubiquitin-proteasome system and promoting the osteogenic transdifferentiation process in VSMCs (Jeon et al., 2006). In addition to the mentioned PTMs of RUNX2, ubiquitination and O-GlcNAcylation (O-linked β-N-acetylglucosamine) modifications also play important roles in regulating the stability and transcriptional activity of RUNX2, and consequently, regulate osteogenic reprogramming and VC in VSMCs (Ong, Han & Yang, 2018; Wells, Vosseller & Hart, 2001; Yamashita et al., 2005; Zhao et al., 2004). Some recent studies have found that microRNAs also regulate the expression of RUNX2 during the osteogenic transdifferentiation process of VSMCs. MicroRNA-32 has been shown to suppress the expression of the tumor suppressor gene PTEN by activating the PI3K signaling pathway, thereby upregulating the transcriptional activity of RUNX2 in VSMCs (Liu et al., 2017). MicroRNA-30b and microRNA-30c have been shown to downregulate the expression of RUNX2 in VSMCs (Balderman et al., 2012). Jeong et al. (2019) found that the overexpression of the long non-coding RNA Lrrc75a-as1 can downregulate the mRNA levels of various osteoblast-related factors such as BMP2, RUNX2 and MSX2 during the osteogenic transdifferentiation process in VSMCs.

Apart from the above-mentioned epigenetic modification mechanisms, current research has found that histone modifications also play an important role in the regulation of RUNX2 expression. The discovered histone deacetylases (HDACs) are roughly divided into four classes: I, II, III and IV, among which class II HDACs primarily regulate the expression of RUNX2 (Eom & Kook, 2014). Abend et al. (2017) found that HDAC4 is upregulated in the early stage of osteogenic transdifferentiation in VSMCs, significantly increasing the expression of the VC marker factors RUNX2 and OPN, while knockdown of HDAC4 by shRNA inhibits the progression of VC. Research by Malhotra et al. (2019) found that in human aortic VSMCs induced for VC, the expression of HDAC9 is increased, thereby upregulating the expression of RUNX2, and knocking down HDAC9 expression with siRNA can inhibit RUNX2 expression and thus VC. Interestingly, HDAC5 and HDAC6, which belong to the same class II HDACs, seem to downregulate the expression of RUNX2 during the osteogenic transdifferentiation of VSMCs (Kwon et al., 2020).

Therefore, it is of great significance to thoroughly investigate the intracellular signaling pathways that upregulate Runx2 expression and the various PTMs that affect RUNX2 activity. This will provide new perspectives for exploring treatments that can inhibit the upregulation of Runx2 expression in VSMCs and thereby reverse osteogenic transdifferentiation.

The interaction between hyperphosphatemia, BMP2, and RUNX2 in the progression of VC

In this review, we have discussed the regulatory roles of hyperphosphatemia, BMP2 and RUNX2 in the progression of vascular calcification. It has been observed that there seems to be a certain interaction among these three in some signaling pathways, and this interaction plays an extremely important role in the regulatory mechanisms of VC progression. Research by Liu et al. (2021) and Zhu et al. (2018) confirmed that the mutual regulation between BMP2 and RUNX2 is realized through the activation of the BMP2/Smad1/5/RUNX2 signaling pathway. The binding of BMP2-mediated Smad1/5 to the nuclear matrix targeting signal domain of RUNX2 can promote the phosphorylation of RUNX2 (Liu et al., 2021; Zhu et al., 2018), and the activated Smad1/5 can also induce the acetylation of RUNX2 to inhibit the degradation of ubiquitinated RUNX2 (Jun et al., 2010). Therefore, BMP2 influences the stability and transcriptional activity of RUNX2 by mediating the activation of Smad1/5, thus regulating the osteogenic transdifferentiation of VSMCs. Consequently, Smad1/5 can be considered as an intermediary that mediates the interaction between BMP2 and RUNX2.

Current research has found that microRNAs also seem to play an important role in the interconnection between BMP2 and RUNX2. BMP2 promotes osteogenic transdifferentiation of VSMCs by downregulating the expression of microRNA-30b and microRNA-30c, which reduces the inhibitory effect of these microRNAs on the expression of RUNX2 (Balderman et al., 2012). Additionally, high concentrations of phosphate can upregulate the expression of BMP2 in VSMCs (Sage et al., 2011; Zhang et al., 2017), and BMP2, in turn, can enhance the uptake of extracellular Pi by VSMCs through the upregulation of Pit-1 expression on the VSMC membrane, further promoting the pathological accumulation of calcium and phosphate and osteogenic transdifferentiation (Li, Yang & Giachelli, 2008). When the extracellular Pi level in VSMCs is elevated, activation of signaling pathways like ERK1/2, NF-kB and WNT/β-catenin upregulate the expression of RUNX2 (Li, Yang & Giachelli, 2006; Yao et al., 2015; Yoshida et al., 2017), which can then mediate an increase in the expression of osteogenic markers such as BMP2, indirectly promoting the uptake of Pi by VSMCs (Voelkl et al., 2019).

In summary, hyperphosphatemia can be seen as the initiating factor in a series of regulatory mechanisms during the VC process secondary to CKD, mediating the expression of BMP2 and RUNX2, which are crucial molecules affecting the VC process. Furthermore, BMP2 and RUNX2 can influence the Pi uptake function of VSMCs through various mechanisms. The individual regulatory roles of these three factors and their complex interactions play an extremely important role in the network of regulatory mechanisms for VC.

Conclusion and Outlook

Vascular calcification is a decisive factor affecting the incidence of cardiovascular events and mortality in the CKD population. During the late stages of CKD, when renal function is severely compromised, serum phosphate levels rise rapidly. The excess extracellular Pi enters the cells via sodium-phosphate cotransporters on the VSMC membrane, activating various intracellular Pi-dependent signaling pathways, which initiate the osteogenic transdifferentiation of VSMCs and VC.

10.7717/peerj.18063/fig-1 Figure 1 The mechanism of vascular calcification involving BMP2 and RUNX2.

Created with Biorender.

BMP2 and RUNX2 serve as key regulatory factors in the process of osteogenic transdifferentiation of VSMCs. They act as downstream molecules with decisive regulatory roles in the series of Pi-dependent signaling pathways that promote VSMC osteogenic transdifferentiation. BMP2 and RUNX2 serve as key factors in the osteogenic transdifferentiation process of VSMCs. Epigenetic modifications occurring at the gene level of these two factors may play a crucial role in the regulatory mechanism. For instance, the acetylation modification of RNA mediated by the recently discovered RNA-binding protein NAT10 has been proven to enhance RNA structural stability, thereby promoting its expression. Based on current research findings, it is speculated that NAT10 may have a regulatory effect on the gene expression of BMP2 and RUNX2 (Arango et al., 2018; Yang et al., 2021). This offers a new perspective for further studies on the molecular mechanisms behind the osteogenic transdifferentiation of VSMCs. In addition, research has found that losartan (a widely used angiotensin II receptor blocker) may inhibit the progression of VC in rats by downregulating the expression of BMP2, RUNX2, and the angiotensin II type 1 receptor (AT1R) in VSMCs. This may provide new research directions for further exploring the specific mechanisms of this drug and for developing clinical treatment strategies targeting BMP2 and RUNX2-mediated VC (Li et al., 2016). In conclusion, these factors are part of a regulatory network centered on Pi that mediates the uptake of extracellular Pi by VSMCs. The complex interactions among Pi, BMP2 and RUNX2 indirectly enhance their positive regulatory effects on the osteogenic transdifferentiation of VSMCs and VC (Fig. 1).

Therefore, more research data is needed to clarify whether Pi, BMP2 and RUNX2 have other potential direct effects on VC and to understand their mechanisms of action. This review will provide new insights and evidence for exploring rational and effective new targets for the clinical treatment of VC secondary to CKD. Identifying such targets could lead to the development of novel therapies that may interrupt the pathological processes underpinning VC in CKD patients, thereby reducing associated morbidity and mortality.

Additional Information and Declarations

Competing Interests

Author Contributions

Data Availability

The authors declare there are no competing interests.

Xinhua Liang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.

Yankun Li analyzed the data, prepared figures and/or tables, and approved the final draft.

Peng Wang conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Huafeng Liu conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

The following information was supplied regarding data availability:

This is a literature review.
==== Refs
References

Abedin et al. (2006) Abedin M Lim J Tang TB Park D Demer LL Tintut Y 2006 N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-gamma pathways Circulation Research 98 727 729 10.1161/01.RES.0000216009.68958.e6 16514067
Abend et al. (2017) Abend A Shkedi O Fertouk M Caspi LH Kehat I 2017 Salt-inducible kinase induces cytoplasmic histone deacetylase 4 to promote vascular calcification EMBO Reports 18 1166 1185 10.15252/embr.201643686 28588072
Agharazii et al. (2015) Agharazii M St-Louis R Gautier-Bastien A Ung RV Mokas S Larivière R Richard DE 2015 Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification American Journal of Hypertension 28 746 755 10.1093/ajh/hpu225 25430697
Alani, Tamimi & Tamimi (2014) Alani H Tamimi A Tamimi N 2014 Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs World Journal of Nephrology 3 156 168 10.5527/wjn.v3.i4.156 25374809
Alesutan et al. (2017) Alesutan I Voelkl J Feger M Kratschmar DV Castor T Mia S Sacherer M Viereck R Borst O Leibrock C Gawaz M Kuro OM Pilz S Tomaschitz A Odermatt A Pieske B Wagner CA Lang F 2017 Involvement of vascular aldosterone synthase in phosphate-induced osteogenic transformation of vascular smooth muscle cells Scientific Reports 7 2059 10.1038/s41598-017-01882-2 28515448
Alves et al. (2014) Alves RD Eijken M Van de Peppel J Van Leeuwen JP 2014 Calcifying vascular smooth muscle cells and osteoblasts: independent cell types exhibiting extracellular matrix and biomineralization-related mimicries BMC Genomics 15 965 10.1186/1471-2164-15-965 25380738
Anonymous (2009) 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney International. Supplement S1 130 10.1038/ki.2009.188
Arango et al. (2018) Arango D Sturgill D Alhusaini N Dillman AA Sweet TJ Hanson G Hosogane M Sinclair WR Nanan KK Mandler MD Fox SD Zengeya TT Andresson T Meier JL Coller J Oberdoerffer S 2018 Acetylation of cytidine in mRNA promotes translation efficiency Cell 175 1872 1886 10.1016/j.cell.2018.10.030 30449621
Balderman et al. (2012) Balderman JA Lee HY Mahoney CE Handy DE White K Annis S Lebeche D Hajjar RJ Loscalzo J Leopold JA 2012 Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification Journal of the American Heart Association 1 e003905 10.1161/jaha.112.003905 23316327
Blacher et al. (2001) Blacher J Guerin AP Pannier B Marchais SJ London GM 2001 Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease Hypertension 38 938 942 10.1161/hy1001.096358 11641313
Block et al. (2004) Block GA Klassen PS Lazarus JM Ofsthun N Lowrie EG Chertow GM 2004 Mineral metabolism, mortality, and morbidity in maintenance hemodialysis Journal of the American Society of Nephrology 15 2208 2218 10.1097/01.Asn.0000133041.27682.A2 15284307
Boström et al. (1993) Boström K Watson KE Horn S Wortham C Herman IM Demer LL 1993 Bone morphogenetic protein expression in human atherosclerotic lesions Journal of Clinical Investigation 91 1800 1809 10.1172/jci116391 8473518
Byon et al. (2008) Byon CH Javed A Dai Q Kappes JC Clemens TL Darley-Usmar VM McDonald JM Chen Y 2008 Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling Journal of Biological Chemistry 283 15319 15327 10.1074/jbc.M800021200 18378684
Cai et al. (2016) Cai T Sun D Duan Y Wen P Dai C Yang J He W 2016 WNT/β-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression Experimental Cell Research 345 206 217 10.1016/j.yexcr.2016.06.007 27321958
Chavkin et al. (2015) Chavkin NW Chia JJ Crouthamel MH Giachelli CM 2015 Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells Experimental Cell Research 333 39 48 10.1016/j.yexcr.2015.02.002 25684711
Chen & Moe (2015) Chen NX Moe SM 2015 Pathophysiology of vascular calcification Current Osteoporosis Reports 13 372 380 10.1007/s11914-015-0293-9 26409849
Chen et al. (2016) Chen J Zhang X Zhang H Liu T Zhang H Teng J Ji J Ding X 2016 Indoxyl sulfate enhance the hypermethylation of klotho and promote the process of vascular calcification in chronic kidney disease International Journal of Biological Sciences 12 1236 1246 10.7150/ijbs.15195 27766038
Chen, Zhao & Wu (2021) Chen Y Zhao X Wu H 2021 Transcriptional programming in arteriosclerotic disease: a multifaceted function of the Runx2 (Runt-Related Transcription Factor 2) Arteriosclerosis, Thrombosis, and Vascular Biology 41 20 34 10.1161/atvbaha.120.313791 33115268
Ciceri & Cozzolino (2021) Ciceri P Cozzolino M 2021 The emerging role of iron in heart failure and vascular calcification in CKD Clinical Kidney Journal 14 739 745 10.1093/ckj/sfaa135 33777358
Collins et al. (2015) Collins AJ Foley RN Gilbertson DT Chen SC 2015 United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease Kidney International. Supplement 2011 5 2 7 10.1038/kisup.2015.2
Cozzolino et al. (2018) Cozzolino M Mangano M Stucchi A Ciceri P Conte F Galassi A 2018 Cardiovascular disease in dialysis patients Nephrology, Dialysis, Transplantation 33 iii28 iii34 10.1093/ndt/gfy174
Dalfino et al. (2010) Dalfino G Simone S Porreca S Cosola C Balestra C Manno C Schena FP Grandaliano G Pertosa G 2010 Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease Atherosclerosis 211 418 423 10.1016/j.atherosclerosis.2010.04.023 20537331
Demer & Tintut (2008) Demer LL Tintut Y 2008 Vascular calcification: pathobiology of a multifaceted disease Circulation 117 2938 2948 10.1161/circulationaha.107.743161 18519861
Deng et al. (2016) Deng D Diao Z Han X Liu W 2016 Secreted frizzled-related protein 5 attenuates high phosphate-induced calcification in vascular smooth muscle cells by inhibiting the Wnt/ß-catenin pathway Calcified Tissue International 99 66 75 10.1007/s00223-016-0117-7 26895007
Deng et al. (2015) Deng L Huang L Sun Y Heath JM Wu H Chen Y 2015 Inhibition of FOXO1/3 promotes vascular calcification Arteriosclerosis, Thrombosis, and Vascular Biology 35 175 183 10.1161/atvbaha.114.304786 25378413
Doherty & Detrano (1994) Doherty TM Detrano RC 1994 Coronary arterial calcification as an active process: a new perspective on an old problem Calcified Tissue International 54 224 230 10.1007/bf00301683 8055371
Durham et al. (2018) Durham AL Speer MY Scatena M Giachelli CM Shanahan CM 2018 Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness Cardiovascular Research 114 590 600 10.1093/cvr/cvy010 29514202
Engelse et al. (2001) Engelse MA Neele JM Bronckers AL Pannekoek H De Vries CJ 2001 Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix gla protein in human atherogenesis Cardiovascular Research 52 281 289 10.1016/s0008-6363(01)00375-3 11684076
Eom & Kook (2014) Eom GH Kook H 2014 Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases Pharmacology and Therapeutics 143 168 180 10.1016/j.pharmthera.2014.02.012 24594235
Goodman et al. (2000) Goodman WG Goldin J Kuizon BD Yoon C Gales B Sider D Wang Y Chung J Emerick A Greaser L Elashoff RM Salusky IB 2000 Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis New England Journal of Medicine 342 1478 1483 10.1056/nejm200005183422003 10816185
Greenblatt et al. (2010) Greenblatt MB Shim JH Zou W Sitara D Schweitzer M Hu D Lotinun S Sano Y Baron R Park JM Arthur S Xie M Schneider MD Zhai B Gygi S Davis R Glimcher LH 2010 The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice Journal of Clinical Investigation 120 2457 2473 10.1172/jci42285 20551513
Hénaut et al. (2018) Hénaut L Chillon JM Kamel S Massy ZA 2018 Updates on the mechanisms and the care of cardiovascular calcification in chronic kidney disease Seminars in Nephrology 38 233 250 10.1016/j.semnephrol.2018.02.004 29753400
Jeon et al. (2006) Jeon EJ Lee KY Choi NS Lee MH Kim HN Jin YH Ryoo HM Choi JY Yoshida M Nishino N Oh BC Lee KS Lee YH Bae SC 2006 Bone morphogenetic protein-2 stimulates Runx2 acetylation Journal of Biological Chemistry 281 16502 16511 10.1074/jbc.M512494200 16613856
Jeong et al. (2019) Jeong G Kwon DH Shin S Choe N Ryu J Lim YH Kim J Park WJ Kook H Kim YK 2019 Long noncoding RNAs in vascular smooth muscle cells regulate vascular calcification Scientific Reports 9 5848 10.1038/s41598-019-42283-x 30971745
Johnson, Leopold & Loscalzo (2006) Johnson RC Leopold JA Loscalzo J 2006 Vascular calcification: pathobiological mechanisms and clinical implications Circulation Research 99 1044 1059 10.1161/01.Res.0000249379.55535.21 17095733
Jun et al. (2010) Jun JH Yoon WJ Seo SB Woo KM Kim GS Ryoo HM Baek JH 2010 BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity Journal of Biological Chemistry 285 36410 36419 10.1074/jbc.M110.142307 20851880
Kwon et al. (2020) Kwon DH Ryu J Kim YK Kook H 2020 Roles of histone acetylation modifiers and other epigenetic regulators in vascular calcification International Journal of Molecular Sciences 21 3246 10.3390/ijms21093246 32375326
Lang et al. (2013) Lang F Ritz E Voelkl J Alesutan I 2013 Vascular calcification—is aldosterone a culprit? Nephrology, Dialysis, Transplantation 28 1080 1084 10.1093/ndt/gft041
Lanzer et al. (2014) Lanzer P Boehm M Sorribas V Thiriet M Janzen J Zeller T Hilaire CSt Shanahan C 2014 Medial vascular calcification revisited: review and perspectives European Heart Journal 35 1515 1525 10.1093/eurheartj/ehu163 24740885
Lee, Lee & Jeon (2020) Lee SJ Lee IK Jeon JH 2020 Vascular calcification-new insights into its mechanism International Journal of Molecular Sciences 21 2685 10.3390/ijms21082685 32294899
Lee et al. (2010) Lee HL Woo KM Ryoo HM Baek JH 2010 Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction Biochemical and Biophysical Research Communications 391 1087 1092 10.1016/j.bbrc.2009.12.027 20004646
Leibrock et al. (2016) Leibrock CB Alesutan I Voelkl J Michael D Castor T Kohlhofer U Quintanilla-Martinez L Kübler L Mannheim JG Pichler BJ Rosenblatt KP Kuro-o M Lang F 2016 Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice Journal of Molecular Medicine (Berl) 94 95 106 10.1007/s00109-015-1331-x
Li et al. (2022) Li SJ Cheng WL Kao YH Chung CC Trang NN Chen YJ 2022 Melatonin inhibits NF-κB/CREB/Runx2 signaling and alleviates aortic valve calcification Frontiers in Cardiovascular Medicine 9 885293 10.3389/fcvm.2022.885293 35795373
Li et al. (2016) Li M Wu P Shao J Ke Z Li D Wu J 2016 Losartan inhibits vascular calcification by suppressing the BMP2 and Runx2 expression in rats in vivo Cardiovascular Toxicology 16 172 181 10.1007/s12012-015-9326-y 25896298
Li, Yang & Giachelli (2006) Li X Yang HY Giachelli CM 2006 Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification Circulation Research 98 905 912 10.1161/01.RES.0000216409.20863.e7 16527991
Li, Yang & Giachelli (2008) Li X Yang HY Giachelli CM 2008 BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells Atherosclerosis 199 271 277 10.1016/j.atherosclerosis.2007.11.031 18179800
Liberman et al. (2011) Liberman M Johnson RC Handy DE Loscalzo J Leopold JA 2011 Bone morphogenetic protein-2 activates NADPH oxidase to increase endoplasmic reticulum stress and human coronary artery smooth muscle cell calcification Biochemical and Biophysical Research Communications 413 436 441 10.1016/j.bbrc.2011.08.114 21907184
Lin et al. (2016) Lin L He Y Xi BL Zheng HC Chen Q Li J Hu Y Ye MH Chen P Qu Y 2016 MiR-135a suppresses calcification in senescent VSMCs by regulating KLF4/STAT3 pathway Current Vascular Pharmacology 14 211 218 10.2174/1570161113666150722151817 26202084
Liu et al. (2014) Liu M Li XC Lu L Cao Y Sun RR Chen S Zhang PY 2014 Cardiovascular disease and its relationship with chronic kidney disease European Review for Medical and Pharmacological Sciences 18 2918 2926 25339487
Liu et al. (2021) Liu J Liu C Qian C Abela G Sun W Kong X 2021 Ginkgo biloba extract EGB761 alleviates warfarin-induced aortic valve calcification through the BMP2/Smad1/5/Runx2 signaling pathway Journal of Cardiovascular Pharmacology 78 411 421 10.1097/fjc.0000000000001082 34132687
Liu et al. (2017) Liu J Xiao X Shen Y Chen L Xu C Zhao H Wu Y Zhang Q Zhong J Tang Z Liu C Zhao Q Zheng Y Cao R Zu X 2017 MicroRNA-32 promotes calcification in vascular smooth muscle cells: implications as a novel marker for coronary artery calcification PLOS ONE 12 e0174138 10.1371/journal.pone.0174138 28319142
Luong et al. (2018) Luong TTD Schelski N Boehme B Makridakis M Vlahou A Lang F Pieske B Alesutan I Voelkl J 2018 Fibulin-3 attenuates phosphate-induced vascular smooth muscle cell calcification by inhibition of oxidative stress Cellular Physiology and Biochemistry 46 1305 1316 10.1159/000489144 29689558
Ma et al. (2019) Ma WQ Sun XJ Wang Y Zhu Y Han XQ Liu NF 2019 Restoring mitochondrial biogenesis with metformin attenuates β-GP-induced phenotypic transformation of VSMCs into an osteogenic phenotype via inhibition of PDK4/oxidative stress-mediated apoptosis Molecular and Cellular Endocrinology 479 39 53 10.1016/j.mce.2018.08.012 30170182
Makarović et al. (2015) Makarović S Makarović Z Steiner R Mihaljević I Milas-Ahić J 2015 Osteoprotegerin and vascular calcification: clinical and prognostic relevance Collegium Antropologicum 39 461 468 26753467
Malhotra et al. (2019) Malhotra R Mauer AC Lino Cardenas CL Guo X Yao J Zhang X Wunderer F Smith AV Wong Q Pechlivanis S Hwang SJ Wang J Lu L Nicholson CJ Shelton G Buswell MD Barnes HJ Sigurslid HH Slocum C Rourke CO Rhee DK Bagchi A Nigwekar SU Buys ES Campbell CY Harris T Budoff M Criqui MH Rotter JI Johnson AD Song C Franceschini N Debette S Hoffmann U Kälsch H Nöthen MM Sigurdsson S Freedman BI Bowden DW Jöckel KH Moebus S Erbel R Feitosa MF Gudnason V Thanassoulis G Zapol WM Lindsay ME Bloch DB Post WS O’Donnell CJ 2019 HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype Nature Genetics 51 1580 1587 10.1038/s41588-019-0514-8 31659325
Martínez-Moreno et al. (2012) Martínez-Moreno JM Muñoz Castañeda JR Herencia C Oca AM Estepa JC Canalejo R Rodríguez-Ortiz ME Perez-Martinez P Aguilera-Tejero E Canalejo A Rodríguez M Almadén Y 2012 In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/β-catenin activation American Journal of Physiology-Renal Physiology 303 F1136 F1144 10.1152/ajprenal.00684.2011 22874762
Moe et al. (2006) Moe S Drüeke T Cunningham J Goodman W Martin K Olgaard K Ott S Sprague S Lameire N Eknoyan G 2006 Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO) Kidney International 69 1945 1953 10.1038/sj.ki.5000414 16641930
Moe et al. (2003) Moe SM Duan D Doehle BP O’Neill KD Chen NX 2003 Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels Kidney International 63 1003 1011 10.1046/j.1523-1755.2003.00820.x 12631081
Ong, Han & Yang (2018) Ong Q Han W Yang X 2018 O-GlcNAc as an integrator of signaling pathways Frontiers in Endocrinology (Lausanne) 9 599 10.3389/fendo.2018.00599
Orth-Alampour et al. (2021) Orth-Alampour S Gayrard N Salem S Bhargava S Jankowski V Jover B Notarnicola C Noels H Van der Vorst EPC Kuppe C Wolf M Goettsch C Theelen W Bruck H Fliser D Loscalzo J Wu Z Marx N Zidek W Argilés À Jankowski J 2021 Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation Basic Research in Cardiology 116 57 10.1007/s00395-021-00899-z 34647168
Ouyang et al. (2021) Ouyang L Su X Li W Tang L Zhang M Zhu Y Xie C Zhang P Chen J Huang H 2021 ALKBH1-demethylated DNA N6-methyladenine modification triggers vascular calcification via osteogenic reprogramming in chronic kidney disease Journal of Clinical Investigation 131 e146985 10.1172/jci146985 34003800
Pei et al. (2020) Pei YQ Zheng YQ Ding YD Xu QX Cao D Wu YN Wang R Yang JX Liang J Ma Q Ge HL 2020 Triptolide attenuates vascular calcification by upregulating expression of miRNA-204 Frontiers in Pharmacology 11 581230 10.3389/fphar.2020.581230 33597871
Pons et al. (2009) Pons D De Vries FR Van den Elsen PJ Heijmans BT Quax PH Jukema JW 2009 Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease European Heart Journal 30 266 277 10.1093/eurheartj/ehn603 19147603
Qiu et al. (2017) Qiu C Zheng H Tao H Yu W Jiang X Li A Jin H Lv A Li H 2017 Vitamin K2 inhibits rat vascular smooth muscle cell calcification by restoring the Gas6/Axl/Akt anti-apoptotic pathway Molecular and Cellular Biochemistry 433 149 159 10.1007/s11010-017-3023-z 28386842
Raggi et al. (2007) Raggi P Bellasi A Ferramosca E Islam T Muntner P Block GA 2007 Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients Kidney International 71 802 807 10.1038/sj.ki.5002164 17311068
Rong et al. (2014) Rong S Zhao X Jin X Zhang Z Chen L Zhu Y Yuan W 2014 Vascular calcification in chronic kidney disease is induced by bone morphogenetic protein-2 via a mechanism involving the Wnt/β-catenin pathway Cellular Physiology and Biochemistry 34 2049 2060 10.1159/000366400 25562153
Sage et al. (2011) Sage AP Lu J Tintut Y Demer LL 2011 Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro Kidney International 79 414 422 10.1038/ki.2010.390 20944546
Sampath & Reddi (1981) Sampath TK Reddi AH 1981 Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation Proceedings of the National Academy of Sciences of the United States of America 78 7599 7603 10.1073/pnas.78.12.7599 6950401
Schlieper et al. (2016) Schlieper G Schurgers L Brandenburg V Reutelingsperger C Floege J 2016 Vascular calcification in chronic kidney disease: an update Nephrology, Dialysis, Transplantation 31 31 39 10.1093/ndt/gfv111
Scimeca et al. (2019) Scimeca M Anemona L Granaglia A Bonfiglio R Urbano N Toschi N Santeusanio G Schiaroli S Mauriello S Tancredi V Schillaci O Bonanno E Mauriello A 2019 Plaque calcification is driven by different mechanisms of mineralization associated with specific cardiovascular risk factors Nutrition, Metabolism and Cardiovascular Diseases 29 1330 1336 10.1016/j.numecd.2019.08.009
Shanahan et al. (1999) Shanahan CM Cary NR Salisbury JR Proudfoot D Weissberg PL Edmonds ME 1999 Medial localization of mineralization-regulating proteins in association with Mönckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification Circulation 100 2168 2176 10.1161/01.cir.100.21.2168 10571976
Shanahan et al. (2011) Shanahan CM Crouthamel MH Kapustin A Giachelli CM 2011 Arterial calcification in chronic kidney disease: key roles for calcium and phosphate Circulation Research 109 697 711 10.1161/circresaha.110.234914 21885837
Shroff, Long & Shanahan (2013) Shroff R Long DA Shanahan C 2013 Mechanistic insights into vascular calcification in CKD Journal of the American Society of Nephrology 24 179 189 10.1681/asn.2011121191 23138485
Smith (2016) Smith ER 2016 Vascular calcification in uremia: new-age concepts about an old-age problem Methods in Molecular Biology 1397 175 208 10.1007/978-1-4939-3353-2_13 26676134
Son et al. (2006) Son BK Kozaki K Iijima K Eto M Kojima T Ota H Senda Y Maemura K Nakano T Akishita M Ouchi Y 2006 Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway Circulation Research 98 1024 1031 10.1161/01.RES.0000218859.90970.8d 16556867
Son et al. (2007) Son BK Kozaki K Iijima K Eto M Nakano T Akishita M Ouchi Y 2007 Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells European Journal of Pharmacology 556 1 8 10.1016/j.ejphar.2006.09.070 17196959
Speer et al. (2010) Speer MY Li X Hiremath PG Giachelli CM 2010 Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis Journal of Cellular Biochemistry 110 935 947 10.1002/jcb.22607 20564193
Speer et al. (2009) Speer MY Yang HY Brabb T Leaf E Look A Lin WL Frutkin A Dichek D Giachelli CM 2009 Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries Circulation Research 104 733 741 10.1161/circresaha.108.183053 19197075
Steitz et al. (2001) Steitz SA Speer MY Curinga G Yang HY Haynes P Aebersold R Schinke T Karsenty G Giachelli CM 2001 Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers Circulation Research 89 1147 1154 10.1161/hh2401.101070 11739279
Sun et al. (2012) Sun Y Byon CH Yuan K Chen J Mao X Heath JM Javed A Zhang K Anderson PG Chen Y 2012 Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification Circulation Research 111 543 552 10.1161/circresaha.112.267237 22773442
Sun et al. (2017) Sun M Chang Q Xin M Wang Q Li H Qian J 2017 Endogenous bone morphogenetic protein 2 plays a role in vascular smooth muscle cell calcification induced by interleukin 6 in vitro International Journal of Immunopathology and Pharmacology 30 227 237 10.1177/0394632016689571 28134597
Taniguchi et al. (2013) Taniguchi M Fukagawa M Fujii N Hamano T Shoji T Yokoyama K Nakai S Shigematsu T Iseki K Tsubakihara Y 2013 Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients Therapeutic Apheresis and Dialysis 17 221 228 10.1111/1744-9987.12030 23551679
Tonelli, Pannu & Manns (2010) Tonelli M Pannu N Manns B 2010 Oral phosphate binders in patients with kidney failure New England Journal of Medicine 362 1312 1324 10.1056/NEJMra0912522 20375408
Tsuji et al. (2006) Tsuji K Bandyopadhyay A Harfe BD Cox K Kakar S Gerstenfeld L Einhorn T Tabin CJ Rosen V 2006 BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing Nature Genetics 38 1424 1429 10.1038/ng1916 17099713
Tyson et al. (2003) Tyson KL Reynolds JL McNair R Zhang Q Weissberg PL Shanahan CM 2003 Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification Arteriosclerosis, Thrombosis, and Vascular Biology 23 489 494 10.1161/01.Atv.0000059406.92165.31 12615658
Viegas et al. (2019) Viegas C Araújo N Marreiros C Simes D 2019 The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts Aging (Albany NY) 11 4274 4299 10.18632/aging.102046 31241466
Voelkl et al. (2013) Voelkl J Alesutan I Leibrock CB Quintanilla-Martinez L Kuhn V Feger M Mia S Ahmed MS Rosenblatt KP Kuro OM Lang F 2013 Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice Journal of Clinical Investigation 123 812 822 10.1172/jci64093 23298834
Voelkl et al. (2019) Voelkl J Lang F Eckardt KU Amann K Kuro OM Pasch A Pieske B Alesutan I 2019 Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia Cellular and Molecular Life Science 76 2077 2091 10.1007/s00018-019-03054-z
Voelkl et al. (2018a) Voelkl J Luong TT Tuffaha R Musculus K Auer T Lian X Daniel C Zickler D Boehme B Sacherer M Metzler B Kuhl D Gollasch M Amann K Müller DN Pieske B Lang F Alesutan I 2018a SGK1 induces vascular smooth muscle cell calcification through NF-κB signaling Journal of Clinical Investigation 128 3024 3040 10.1172/jci96477 29889103
Voelkl et al. (2018b) Voelkl J Tuffaha R Luong TTD Zickler D Masyout J Feger M Verheyen N Blaschke F Kuro OM Tomaschitz A Pilz S Pasch A Eckardt KU Scherberich JE Lang F Pieske B Alesutan I 2018b Zinc inhibits phosphate-induced vascular calcification through TNFAIP3-mediated suppression of NF-κB Journal of the American Society of Nephrology 29 1636 1648 10.1681/asn.2017050492 29654213
Vogt, Haffner & Leifheit-Nestler (2019) Vogt I Haffner D Leifheit-Nestler M 2019 FGF23 and phosphate-cardiovascular toxins in CKD Toxins (Basel) 11 647 10.3390/toxins11110647 31698866
Wang et al. (1990) Wang EA Rosen V D’Alessandro JS Bauduy M Cordes P Harada T Israel DI Hewick RM Kerns KM LaPan P 1990 Recombinant human bone morphogenetic protein induces bone formation Proceedings of the National Academy of Sciences of the United States of America 87 2220 2224 10.1073/pnas.87.6.2220 2315314
Wells, Vosseller & Hart (2001) Wells L Vosseller K Hart GW 2001 Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc Science 291 2376 2378 10.1126/science.1058714 11269319
Xiao et al. (2000) Xiao G Jiang D Thomas P Benson MD Guan K Karsenty G Franceschi RT 2000 MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1 Journal of Biological Chemistry 275 4453 4459 10.1074/jbc.275.6.4453 10660618
Xu et al. (2017) Xu M Liu L Song C Chen W Gui S 2017 Ghrelin improves vascular autophagy in rats with vascular calcification Life Sciences 179 23 29 10.1016/j.lfs.2016.11.025 27916732
Yamada & Giachelli (2017) Yamada S Giachelli CM 2017 Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and Klotho Bone 100 87 93 10.1016/j.bone.2016.11.012 27847254
Yamada et al. (2018) Yamada S Leaf EM Chia JJ Cox TC Speer MY Giachelli CM 2018 PiT-2, a type III sodium-dependent phosphate transporter, protects against vascular calcification in mice with chronic kidney disease fed a high-phosphate diet Kidney International 94 716 727 10.1016/j.kint.2018.05.015 30041812
Yamada et al. (2014) Yamada S Tokumoto M Tatsumoto N Taniguchi M Noguchi H Nakano T Masutani K Ooboshi H Tsuruya K Kitazono T 2014 Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia American Journal of Physiology-Renal Physiology 306 F1418 F1428 10.1152/ajprenal.00633.2013 24808541
Yamashita et al. (2005) Yamashita M Ying SX Zhang GM Li C Cheng SY Deng CX Zhang YE 2005 Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation Cell 121 101 113 10.1016/j.cell.2005.01.035 15820682
Yanagawa et al. (2012) Yanagawa B Lovren F Pan Y Garg V Quan A Tang G Singh KK Shukla PC Kalra NP Peterson MD Verma S 2012 miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis Journal of Thoracic and Cardiovascular Surgery 144 256 262 10.1016/j.jtcvs.2011.10.097 22336757
Yang et al. (2021) Yang W Li HY Wu YF Mi RJ Liu WZ Shen X Lu YX Jiang YH Ma MJ Shen HY 2021 ac4C acetylation of RUNX2 catalyzed by NAT10 spurs osteogenesis of BMSCs and prevents ovariectomy-induced bone loss Molecular Therapy—Nucleic Acids 26 135 147 10.1016/j.omtn.2021.06.022 34513300
Yang et al. (2018) Yang Y Sun Y Chen J Bradley WE Dell’Italia LJ Wu H Chen Y 2018 AKT-independent activation of p38 MAP kinase promotes vascular calcification Redox Biology 16 97 103 10.1016/j.redox.2018.02.009 29495001
Yang et al. (2020) Yang P Troncone L Augur ZM Kim SSJ McNeil ME Yu PB 2020 The role of bone morphogenetic protein signaling in vascular calcification Bone 141 115542 10.1016/j.bone.2020.115542 32736145
Yao et al. (2015) Yao L Sun YT Sun W Xu TH Ren C Fan X Sun L Liu LL Feng JM Ma JF Wang LN 2015 High phosphorus level leads to aortic calcification via β-catenin in chronic kidney disease American Journal of Nephrology 41 28 36 10.1159/000370250 25634106
Yoshida et al. (2017) Yoshida T Yamashita M Horimai C Hayashi M 2017 Smooth muscle-selective nuclear factor-κB inhibition reduces phosphate-induced arterial medial calcification in mice with chronic kidney disease Journal of the American Heart Association 6 e007248 10.1161/jaha.117.007248 29146611
Yung et al. (2015) Yung LM Sánchez-Duffhues G Ten Dijke P Yu PB 2015 Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells Cardiovascular Research 108 278 287 10.1093/cvr/cvv221 26410368
Zeng et al. (2021) Zeng P Yang J Liu L Yang X Yao Z Ma C Zhu H Su J Zhao Q Feng K Yang S Zhu Y Li X Wang W Duan Y Han J Chen Y 2021 ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway Theranostics 11 1129 1146 10.7150/thno.49771 33391525
Zhang et al. (2017) Zhang D Bi X Liu Y Huang Y Xiong J Xu X Xiao T Yu Y Jiang W Huang Y Zhang J Zhang B Zhao J 2017 High phosphate-induced calcification of vascular smooth muscle cells is associated with the TLR4/NF-κb signaling pathway Kidney and Blood Pressure Research 42 1205 1215 10.1159/000485874 29227975
Zhao et al. (2004) Zhao M Qiao M Harris SE Oyajobi BO Mundy GR Chen D 2004 Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo Journal of Biological Chemistry 279 12854 12859 10.1074/jbc.M313294200 14701828
Zhao et al. (2012) Zhao G Xu MJ Zhao MM Dai XY Kong W Wilson GM Guan Y Wang CY Wang X 2012 Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression Kidney International 82 34 44 10.1038/ki.2012.40 22437419
Zhu et al. (2018) Zhu Z Xie Q Huang Y Zhang S Chen Y 2018 Aucubin suppresses Titanium particles-mediated apoptosis of MC3T3-E1 cells and facilitates osteogenesis by affecting the BMP2/Smads/RunX2 signaling pathway Molecular Medicine Reports 18 2561 2570 10.3892/mmr.2018.9286 30015916
